1. Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs
- Author
-
Shelley N. Facente, Peter Vickerman, Jennifer Hecht, Kimberly Page, Willi McFarland, Erin C. Wilson, Katie Burk, Hannah Fraser, Sheena Patel, and Meghan D. Morris
- Subjects
Male ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,Medical and Health Sciences ,Hepatitis ,Men who have sex with men ,Sexual and Gender Minorities ,Substance Abuse, Intravenous ,education.field_of_study ,Liver Disease ,Substance Abuse ,virus diseases ,Homosexuality ,Hepatitis C ,Biological Sciences ,Infectious Diseases ,Pharmaceutical Preparations ,care cascade ,Female ,Intravenous ,Infection ,Adult ,Microbiology (medical) ,Low income ,transgender women ,medicine.medical_specialty ,Adolescent ,Hepatitis C virus ,Chronic Liver Disease and Cirrhosis ,Population ,Sexual and Gender Minorities (SGM/LGBT*) ,Microbiology ,Unmet needs ,Vaccine Related ,Hepatitis - C ,Internal medicine ,Behavioral and Social Science ,medicine ,Humans ,MSM ,Homosexuality, Male ,Online Only Articles ,PWID ,education ,business.industry ,Prevention ,medicine.disease ,Cross-Sectional Studies ,Emerging Infectious Diseases ,Good Health and Well Being ,Virologic response ,hepatitis C ,Digestive Diseases ,business ,Limited resources - Abstract
Background To achieve elimination of hepatitis C virus (HCV) infection, limited resources can be best allocated through estimation of “care cascades” among groups disproportionately affected. In San Francisco and elsewhere, these groups include young (age ≤ 30 years) people who inject drugs (YPWID), men who have sex with men who inject drugs (MSM-IDU), and low-income trans women. Methods We developed cross-sectional HCV care cascades for YPWID, MSM-IDU, and trans women using diverse data sources. Population sizes were estimated using an inverse variance-weighted average of estimates from the peer-reviewed literature between 2013 and 2019. Proportions of past/current HCV infection, diagnosed infection, treatment initiation, and evidence of cure (sustained virologic response at 12 weeks posttreatment) were estimated from the literature using data from 7 programs and studies in San Francisco between 2015 and 2020. Results The estimated number of YPWID in San Francisco was 3748; 58.4% had past/current HCV infection, of whom 66.4% were diagnosed with current infection, 9.1% had initiated treatment, and 50% had confirmed cure. The corresponding figures for the 8135 estimated MSM-IDU were: 29.4% with past/current HCV infection, 70.3% diagnosed with current infection, 28.4% initiated treatment, and 38.9% with confirmed cure. For the estimated 951 low-income trans women, 24.8% had past/current HCV infection, 68.9% were diagnosed with current infection, 56.5% initiated treatment, and 75.5% had confirmed cure. Conclusions In all 3 populations, diagnosis rates were relatively high; however, attention is needed to urgently increase treatment initiation in all groups, with a particular unmet need among YPWID.
- Published
- 2021